Evidence map›Paper›PMID 36525434›Full record

ArticlePloS one2022

Clinical and laboratory characterization of adult sickle cell anemia patients in Kinshasa.

Paul Kabuyi Lumbala, Gloire Mbayabo, Mamy Nzita Ngole, Aimé Lumaka, Valerie Race, Gert Matthijs, Chris Van Geet, Prosper Tshilobo Lukusa, Koenraad Devriendt, Tite Minga Mikobi

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 2 countries.

Paul Kabuyi LumbalaDepartment of Pediatrics, University of Kinshasa, Kinshasa, DRC.
Gloire MbayaboDepartment of Pediatrics, University of Kinshasa, Kinshasa, DRC.ORCID 0000-0002-6887-4092
Mamy Nzita NgoleDepartment of Clinical Biology, University of Kinshasa, Kinshasa, DRC.
Aimé LumakaFaculty of Medicine, Center of Human Genetics, University of Kinshasa, Kinshasa, DRC.ORCID 0000-0002-5468-8678
Valerie RaceCenter for Human Genetics, KU Leuven and University Hospitals Leuven, Leuven, Belgium.
Gert MatthijsCenter for Human Genetics, KU Leuven and University Hospitals Leuven, Leuven, Belgium.
Chris Van GeetDepartment of Cardiovascular Sciences, Center for Molecular and Vascular Biology, KU Leuven, Leuven, Belgium.
Prosper Tshilobo LukusaFaculty of Medicine, Center of Human Genetics, University of Kinshasa, Kinshasa, DRC.
Koenraad DevriendtCenter for Human Genetics, KU Leuven and University Hospitals Leuven, Leuven, Belgium.ORCID 0000-0002-3651-2548
Tite Minga MikobiFaculty of Medicine, Center of Human Genetics, University of Kinshasa, Kinshasa, DRC.ORCID 0000-0003-0809-3304
University of Kinshasa · CDKU Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSickle cell anemia (SCA) is a monogenic hemoglobinopathy associated with severe acute and chronic complications, with the highest incidence worldwide in Sub-Saharan Africa. The wide variability in clinical manifestations suggest that a uniform response to hydroxurea may not be attained. In view of a potential treatment with hydroxyurea (HU), we assessed the variability of clinical and hematological manifestations in a cohort of adults with SCA in Kinshasa, capital of the DR Congo in Central Africa.

methodsA cross-sectional study was conducted in a hospital dedicated to SCA management in Kinshasa. Clinical history of patients was recorded, a complete physical examination performed. The diagnosis was confirmed by means of DNA analysis. A full blood count and hemolysis markers were measured. The severity of the disease was evaluated by means of a previously reported score.

resultsThe study group consisted of 166 genetically confirmed SCA patients. The SCA severity was mild in 28.9%, moderate in 64.5% and severe in 6.6%. The disease severity score increased with patient's age (p ≤ 0.001). The severity was higher in males compared to females (p = 0.012). In males, the severity score was correlated with the presence of priapism (p = 0.045), a manifestation not previously incorporated in the severity score. The severity score was inversely correlated with the fetal hemoglobin (HbF) rate (p = 0.005). Malnutrition (BMI <18.5 kg/m2) was present in 47% of patients and was related to the male sex, hip disease (aOR 3.11; p = 0.019) and severe phenotype (aOR 3.53; p = 0.012). Leg ulcers were more frequent in males than in females (p = 0.001; OR 24.3) and were correlated with the number of days of hospitalization (p = 0.029). Hip disease was related to the increasing age (p = 0.008).

conclusionIn this selected, hospital-based populations of adults with SCA, severe disease was rare, which may be due to survival bias. However, two thirds had moderate severity of the disease, mostly with a low HbF, and they may benefit from HU treatment. In the Central-African setting the separation between vaso-occlusive and hyperhemolytic sub-phenotypes was not applicable.

Indexed as

Anemia, Sickle CellCross-Sectional StudiesDemocratic Republic of the CongoFemaleFetal HemoglobinHumansHydroxyureaMaleFetal HemoglobinHydroxyurea

Identifiers

PMID36525434
PMCPMC9757547
OpenAlexW4311651311

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.